Last reviewed · How we verify
CG200745 PPA
At a glance
| Generic name | CG200745 PPA |
|---|---|
| Also known as | CG200745 PPA (phosphoric acid) |
| Sponsor | CrystalGenomics, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase 1/2 Study of CG200745 PPA for Myelodysplastic Syndrome (PHASE1, PHASE2)
- Study of CG200745 PPA in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CG200745 PPA CI brief — competitive landscape report
- CG200745 PPA updates RSS · CI watch RSS
- CrystalGenomics, Inc. portfolio CI